Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT):48 week results from a randomised, open-label, non-inferiority trial (vol 15, pg 775, 2015)

Perez-Molina J. A.; Rubio R.; Rivero A.

首页> 外文期刊>The Lancet infectious diseases >Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT):48 week results from a randomised, open-label, non-inferiority trial (vol 15, pg 775, 2015)

【24h】

Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT):48 week results from a randomised, open-label, non-inferiority trial (vol 15, pg 775, 2015)

机译：在病毒学稳定的HIV-1（SALT）患者中，使用atazanavir-ritonavir加拉米夫定双重治疗与使用atazanavir-ritonavir加两个核苷三联治疗：48周来自一项随机，开放标签，非劣效性试验（第15卷，第775页，2015年）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Lancet infectious diseases》 |2015年第9期|共1页
作者
Perez-Molina J. A.; Rubio R.; Rivero A.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词

相似文献

外文文献
中文文献

1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT):48 week results from a randomised, open-label, non-inferiority trial (vol 15, pg 775, 2015) [J] . Perez-Molina J. A., Rubio R., Rivero A. The Lancet infectious diseases . 2015,第9期

机译：在病毒学稳定的HIV-1（SALT）患者中，使用atazanavir-ritonavir加拉米夫定双重治疗与使用atazanavir-ritonavir加两个核苷三联治疗：48周来自一项随机，开放标签，非劣效性试验（第15卷，第775页，2015年）
2. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial (vol 15, pg 785, 2015) [J] . Arribas Jose R., Girard Pierre-Marie, Landman Roland The Lancet infectious diseases . 2015,第8期

机译：洛匹那韦-利托那韦加拉米夫定的双重治疗与洛匹那韦-利托那韦加拉米夫定或恩曲他滨和第二个核苷酸（t）逆转录酶抑制剂用于维持HIV-1病毒抑制（OLE）的三重治疗：随机，开放标签，非自卑审判（2015年第15卷，第785页）
3. Simplification to dual therapy (atazanavir/ritonavir plus lamivudine) versus standard triple therapy [atazanavir/ritonavir plus two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study) [J] . Perez-Molina J. A., Rubio R., Rivero A., The Journal of Antimicrobial Chemotherapy . 2017,第1期

机译：简化双重治疗（Atazanavir / Ritonavir Plus Lamivudine）与标准三重疗法[Atazanavir / Ritonavir加上两种核核患者在抗逆转录病毒治疗患者中：96周的开放标签，非劣质性，随机临床试验（盐研究）
4. Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized Double-Blind Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir Emtricitabine and Tenofovir Alafenamide versus Co-formulated Abacavir Dolutegravir and Lamivudine [O] . David Wohl, Amanda Clarke, Franco Maggiolo, -1

机译：在联合配制的比格韦恩曲他滨和替诺福韦阿拉芬酰胺与联合配制的阿巴卡韦多洛格韦和拉米夫定联合治疗的成人HIV随机双盲III期非劣效性试验参与者中患者报告的症状超过48周
5. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial [O] . David A Wohl, Yazdan Yazdanpanah, Axel Baumgarten, 2019

机译：Bictegravir与Emtricitabine和Tenofovir Alafenainide相结合，与Dolutegravir，Abacavir和Lamivudine进行HIV-1感染的初始治疗：第96周的随机，双盲，多期，第3期，非劣级试验结果

Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT):48 week results from a randomised, open-label, non-inferiority trial (vol 15, pg 775, 2015)

著录项

相似文献

相关主题

期刊订阅